| Dr Joseph Raymund Feliciano, MD | |
|
1250 S Cedar Crest Blvd, Suite 210, Allentown, PA 18103-6224 | |
| (610) 402-6986 | |
| (610) 402-1682 |
| Full Name | Dr Joseph Raymund Feliciano |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 19 Years |
| Location | 1250 S Cedar Crest Blvd, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902003338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | MD442732 (Pennsylvania) | Primary |
| 208800000X | Urology | 257208 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Home Care | Allentown, PA | Home health agency |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Lehigh Valley Hospital - Pocono | East stroudsburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
The complete agenda for the Seventh International Chronic Total Occlusion (CTO) Summit is now available online at http://www.ctosummit.org/overview/agenda.html. The CTO Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.
A new Personal Relationships study documents how the quality of a person's romantic relationship and the life stress he or she experiences at two key points in early adulthood (at age 23 and 32) are related to sleep quality and quantity in middle adulthood (at age 37).
While network algorithms are usually associated with finding friends on social media, researchers at the University of Sussex have shown how they could also be used improve the effectiveness of cancer treatment, by predicting the interactions between genes.
Medical device manufacturers are developing products that are less invasive, contribute to faster medical procedures and help speed patient recovery. To accomplish this, they are increasingly utilizing advanced, biocompatible thermoplastics in their medical devices.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 7 days ago
| Entity Name | Family Care Centers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669563037 PECOS PAC ID: 5395649347 Enrollment ID: O20031121000497 |
News Archive
The complete agenda for the Seventh International Chronic Total Occlusion (CTO) Summit is now available online at http://www.ctosummit.org/overview/agenda.html. The CTO Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.
A new Personal Relationships study documents how the quality of a person's romantic relationship and the life stress he or she experiences at two key points in early adulthood (at age 23 and 32) are related to sleep quality and quantity in middle adulthood (at age 37).
While network algorithms are usually associated with finding friends on social media, researchers at the University of Sussex have shown how they could also be used improve the effectiveness of cancer treatment, by predicting the interactions between genes.
Medical device manufacturers are developing products that are less invasive, contribute to faster medical procedures and help speed patient recovery. To accomplish this, they are increasingly utilizing advanced, biocompatible thermoplastics in their medical devices.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 7 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
The complete agenda for the Seventh International Chronic Total Occlusion (CTO) Summit is now available online at http://www.ctosummit.org/overview/agenda.html. The CTO Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.
A new Personal Relationships study documents how the quality of a person's romantic relationship and the life stress he or she experiences at two key points in early adulthood (at age 23 and 32) are related to sleep quality and quantity in middle adulthood (at age 37).
While network algorithms are usually associated with finding friends on social media, researchers at the University of Sussex have shown how they could also be used improve the effectiveness of cancer treatment, by predicting the interactions between genes.
Medical device manufacturers are developing products that are less invasive, contribute to faster medical procedures and help speed patient recovery. To accomplish this, they are increasingly utilizing advanced, biocompatible thermoplastics in their medical devices.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 7 days ago
| Entity Name | Hazleton Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952464638 PECOS PAC ID: 8022110402 Enrollment ID: O20070305000195 |
News Archive
The complete agenda for the Seventh International Chronic Total Occlusion (CTO) Summit is now available online at http://www.ctosummit.org/overview/agenda.html. The CTO Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.
A new Personal Relationships study documents how the quality of a person's romantic relationship and the life stress he or she experiences at two key points in early adulthood (at age 23 and 32) are related to sleep quality and quantity in middle adulthood (at age 37).
While network algorithms are usually associated with finding friends on social media, researchers at the University of Sussex have shown how they could also be used improve the effectiveness of cancer treatment, by predicting the interactions between genes.
Medical device manufacturers are developing products that are less invasive, contribute to faster medical procedures and help speed patient recovery. To accomplish this, they are increasingly utilizing advanced, biocompatible thermoplastics in their medical devices.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Raymund Feliciano, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: () - | Dr Joseph Raymund Feliciano, MD 1250 S Cedar Crest Blvd, Suite 210, Allentown, PA 18103-6224 Ph: (610) 402-6986 |
News Archive
The complete agenda for the Seventh International Chronic Total Occlusion (CTO) Summit is now available online at http://www.ctosummit.org/overview/agenda.html. The CTO Summit is a two-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions.
A new Personal Relationships study documents how the quality of a person's romantic relationship and the life stress he or she experiences at two key points in early adulthood (at age 23 and 32) are related to sleep quality and quantity in middle adulthood (at age 37).
While network algorithms are usually associated with finding friends on social media, researchers at the University of Sussex have shown how they could also be used improve the effectiveness of cancer treatment, by predicting the interactions between genes.
Medical device manufacturers are developing products that are less invasive, contribute to faster medical procedures and help speed patient recovery. To accomplish this, they are increasingly utilizing advanced, biocompatible thermoplastics in their medical devices.
Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
› Verified 7 days ago
Kiranpreet Kaur Khurana, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd Ste 215, Allentown, PA 18103 Phone: 610-402-6986 Fax: 610-402-4460 | |
Jonathan B Bingham, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd Ste 215, Allentown, PA 18103 Phone: 484-884-0617 Fax: 484-884-0628 | |
Dr. Brian P Murphy, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5018 Medical Center Cir, Suite 101b, Allentown, PA 18106 Phone: 484-876-5649 | |
Dr. Joseph Pascal, MD Urology Medicare: Medicare Enrolled Practice Location: 1250 S Cedar Crest Blvd Ste 215, Allentown, PA 18103 Phone: 610-402-6986 Fax: 610-402-4460 | |
Dr. John Samuel Jaffe, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1605 N Cedar Crest Blvd, Suite 411, Allentown, PA 18104 Phone: 610-969-0199 | |
Dr. Paul M Berger, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5018 Medical Center Cir, Suite 240, Allentown, PA 18106 Phone: 484-876-5649 Fax: 610-841-3914 | |
Dr. James Robert Johannes, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 210, Allentown, PA 18103 Phone: 610-402-6986 Fax: 610-402-1682 |